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Materials and Methods: 20 cervical cancer patients who 
underwent treatment at Royal Marsden Hospital were 
identified retrospectively. Both EBRT and BT plans were 
retrieved from radiotherapy archive. The plans were 
anonymised and transferred to VODCA-RT (MSS 
GmbH,Hagendorn,CH) which is a dosimetric analysis 
software. The rectum was recontoured using standardised 
anatomical definition of 2.5cm from anal canal to the 
rectosigmoid junction. Posteriorly cut DSM were generated 
using VODCA-RT for both EBRT and BT. The raw data was 
then organised using in-house R script before being 
normalised to 21x21 pixels using MATLAB (Mathworks, Natick, 
MA). Assuming an α/β ratio of the linear quadratic model of 
3Gy for the rectum, equivalent BED dose in 2Gy conversion 
was made using the equation shown below.  
 
Dose values of corresponding pixels were then summated to 
derive the respective DSM. Maximum rectal toxicity such as 
bleeding and proctitis within 6 months of treatment were 
also recorded using CTCAE v4.0. Statistical analysis was 
performed using MedCalc software v14.10.2. 
Results: Combined rectal DSM were successfully generated 
for all 20 patients using our methodology. An example of a 
combined DSM is illustrated in figure 1. As expected, there 
was significant variation between the mean rectal volume 
during EBRT and BT (67.71cc and 53.99cc respectively, 
p=0.0189) due to presence of brachytherapy applicator and 
rectal retractor. There was also a mean difference of 0.59cm 
between EBRT and BT rectal cranio-caudal length (p=0.049). 
This is most likely to be due to true anatomical variation 
between both time points e.g. angulation of upper rectum. 
Normalisation to 21x21 pixels was therefore felt to be a good 
compromise to account for these anatomical differences 
whilst maintaining relatively accurate spatial dose 
distribution following dose summation. Consistent with 
previously published study by Buettner et al, ROC analysis on 
our data also demonstrated that lateral extent (rectal 
circumference) receiving >60Gy is a good predictor of risk of 
G1-3 proctitis (AUC=0.879,p<0.0001). 
 
 
Conclusions: Rectal dose summation using DSM for cervical 
EBRT and BT is feasible. This method retains valuable spatial 
information which is closely correlated to toxicity. We 
propose a follow-up study with a bigger cohort incorporating 
organ motion for further validation of DSM as alternative 
eassessment of rectal constraints in cervical cancer patients. 
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Purpose/Objective: Radical radiation therapy comprising of 
external beam radiotherapy(EBRT) and intracavitary 
brachytherapy with concurrent chemotherapy,is the gold 
standard for management of locally advanced cervical 
cancers. Brachytherapy forms the mainstay of treatment for 
local control rates and toxicities.Recent reports indicate that 
image-guided BT (IGBT) improves local control and late 
morbidity. MR imaging is the gold standard for IGBT practice 
which have been well described in GEC-ESTRO I-IV 
recommendations.However, various survey reports suggest 
the limited availability of MR and logistics with radiology 
units.On the other hand,CT Imaging is available in the 
radiotherapy units. There has been an increased interest in 
the use of CT during IGBT in Cervical Cancers. With an aim to 
validate CT based IGBT in terms of OAR and HR-CTV 
contouring we undertook this sub-study as a part of ongoing 
prospective EMBRACE study.  
Materials and Methods: Patients who were recruited for the 
EMBRACE study ,after completion of EBRT,underwent BT 
application with MR/CT compatible applicators. A planning 
CT with I.V contrast and appropriate bladder filling protocol 
followed by T2w-MR Imaging for BT planning was performed. 
HR-CTV and OAR's were contoured on CT images based on 
pre-Rx MR, clinical findings at diagnosis and at BT.First the 
contouring was done on CT images followed by on T2w-MR 
Images.HR-CTV and OAR volumes and HR-CTV dimensions 
(height, width and thickness) were analyzed and compared.  
Results: So far, 27 patients (Mean Age:47±8.4 years) with 
histologically proven cervical cancer,with FIGO (2009) Stage 
IB to IIIB (IB2-1,IIB-13, IIIB-12, IVA-1) who underwent CT and 
MR during IGBT process were analyzed.The mean + SD 
volumes of rectum, bladder and sigmoid on CT was 40 ± 20.0 
cc, 79 ± 30.6 cc and 40.4 ± 26.7 cc as compared to 33 ± 11.6 
cc, 84.7 ± 29.6 cc, 35.6 ± 19.7 cc on MR respectively.The 
mean + SD HR-CTV on CT was 41.3 ± 23.6 cc while it was 42 ± 
23.6 cc on MRI with a Pearson's correlation co-efficient of 
0.921 (p<0.001).The mean + SD maximum height, width and 
thickness on CT was 44.4 ± 10.5mm, 47.6 ± 6mm and 33.5 ± 
5.3mm while it was 44.8 ± 10.5mm, 46 ± 7.2mm and 34.8 ± 
7.5mm on MR. The correlation coefficients were 0.73 (p = 
0.00) for height,0.61 (p<0.00) for width and 0.76 (p<0.00) for 
thickness.Since the correlation for width was least, we 
divided the patients into 3 groups:no parametrial 
invasion,medial parametrial invasion and lateral parametrial 
invasion at the time of BT. The correlation coefficient were 
0.76 (p <0.00), 0.77 (p <0.00) and 0.54 ( p <0.53 ) for the 
three groups respectively. To estimate the differences 
further,the mean+ SD difference between CT and MR for 
various dimensions were as follows: 0.37 ± 7.6mm for height, 
-1.5 ± 4.8 mm for width and 1.3 ±5.9 mm or thickness 
respectively.  
Conclusions: As compared to MR Based contouring,the OAR 
and HR-CTV volumes are comparable.On evaluation of HRCTV 
maximum dimensions,the correlation was highest for 
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thickness while least for the width.The maximum width is 
overestimated especially when the parametrial invasion is 
present at BT with CT based contouring. 
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Purpose/Objective: To compare the maximum target 
dimensions and image quality between magnetic resonance 
imaging (MRI), transrectal ultrasound (TRUS) and computed 
tomography (CT) in image guided adaptive brachytherapy 
(IGABT) of locally advanced cervical cancer 
Materials and Methods: All patients with locally advanced 
cervical cancer treated with radiochemotherapy and IGABT 
between 09/2012-05/2013 were included in this study. T2-
weighted MRI (1.5 tesla), TRUS and CT were performed 
before (MRIpreBT, TRUSpreBT) and / or after (MRIBT, TRUSBT and 
CTBT) insertion of the applicator. 3D TRUS image acquisition 
was done with a customized US stepper device and software. 
The target was defined on 3D image sequences acquired with 
different imaging modalities by one blinded observer, in 
accordance to the GEC-ESTRO recommendations for MRI-
based target volume delineation, as the complete cervical 
mass including the tumour, any suspicious areas of 
parametrial involvement and the normal cervical stroma. 
Maximum target width and thickness were measured on 
transversal planes. Image quality was classified using the 
following scoring system: Grade 0: not depicted, Grade 1: 
inability to discriminate, margin not recognizable, Grade 2: 
fair discrimination, margin indistinct, Grade 3: excellent 
discrimination, margin distinct. Descriptive statistics, mean 
differences between the groups, with MRIBT as reference, and 
a paired t-test were calculated.  
Results: Images from 21 patients (FIGO IB: 3, IIB: 11, IIIB: 5, 
IVB: 2) were available for analysis. The mean difference in 
maximum target width of TRUSBT, TRUSpreBT, MRIpreBT, CTBT to 
MRIBT was 0.5mm ±5.5 (n.s.), -1.7mm ±5.7 (n.s.), 0.0mm ±5.7 
(n.s.) and 12.9mm ±6.1 (p < 0.001) (figure 1). The mean 
difference in maximum target thickness of TRUSBT, TRUSpreBT, 
MRIpreBT, CTBT to MRIBT was -3.5mm ±5.5 (p=0.012), -7.6mm 
±4.3 (p <0.001), 0.5mm ±6.4 (n.s.) and 11.8mm ±6.3 (p < 
0.001). Mean scores of image quality of the target volume 
was 2.9 for TRUSpreBT, 2.3 for TRUSBT, 2.9 for MRIpreBT, 2.7 for 
MRIBT and 2.1 for CTBT. 
Conclusions: TRUS seems to be superior to CT for assessment 
of the target volume in IGABT of cervical cancer as it yields 
systematically smaller deviations from the gold standard T2-
weighted MRI, with reasonable image quality. Differences of 
TRUS target thickness might likely be related to differences 
in image slice orientation and compression of the target 
volume by the TRUS probe before insertion of the 
brachytherapy applicator.  
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Purpose/Objective: To assess the use of brachytherapy with 
or without external beam radiation in medically inoperable 
stage I endometrial adenocarcinoma in the United States and 
to determine the effect of brachytherapy on overall survival 
(OS) and cause specific survival (CSS). 
Materials and Methods: Data between 1998 and 2011 from 
the National Cancer Institute's Surveillance, Epidemiology and 
End Results (SEER) database were analyzed. Coarsened exact 
matching was used to adjust for differences in age, grade and 
year of diagnosis between patients who received 
brachytherapy and those who did not. Prognostic factors 
affecting OS and CSS including age, grade, race, marital 
status, metropolitan residential area, and year of diagnosis 
were evaluated using Kaplan Meier product-limit method and 
Cox proportional hazards regression model. Cumulative 
incidence was calculated using a competing risks model. 
Results: A total of 460 patients with inoperable stage I 
endometrial adenocarcinoma treated with radiation therapy 
were identified. Radiation consisted of either external beam 
radiation (n=260) or brachytherapy with or without external 
beam radiation (n=200). The only factor associated with 
brachytherapy use was younger patient age (median age: 72 
vs. 76, p=0.001). Median survival for all patients was 40 
months. Patients who received brachytherapy had a higher 3 
year OS (OS: 60% vs. 47%, p<0.001) and CSS (CSS: 82% vs. 74%, 
p=0.032) compared to those who did not. On multivariate 
analysis, brachytherapy use was independently associated 
with an improved OS (OS: hazard ratio [HR]=0.68, 95% 
confidence interval [CI]: 0.52 – 0.87) and CSS (CSS: HR=0.61, 
95% CI: 0.39 – 0.93). In the matched cohort of patients 
(n=260), the OS benefit associated with brachytherapy 
remained significant on multivariate analysis (OS: HR=0.65, 
95% CI: 0.47 - 0.88). Brachytherapy was also associated with 
a lower 2 year cumulative incidence of cancer specific death 
(19% vs. 13%). 
Conclusions: Brachytherapy is independently associated with 
an improved OS. It should be considered as part of the 
treatment regimen for all stage I inoperable endometrial 
patients undergoing radiation.  
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